CTOs on the Move

Topigen Pharmaceuticals

www.topigen.com

 
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.topigen.com
  • 4050 rue Molson St Ste 300
    MontríŠal, QC CAN H1Y 3N1
  • Phone: 514.868.0077

Executives

Name Title Contact Details

Similar Companies

Galera Therapeutics

Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.

Amplity

You knew us as PHS Health Solutions, Touchpoint, Tardis Medical, and PDI, a family of leading pharmaceutical contract commercial organizations with a reputation as a trusted partner to our clients. And we`re still all that - but now we`re Amplity Health. Our vision is singular, so we wanted our corporate identity to match. We`ve consolidated our family of brands to offer customized and multichannel medical, remote engagement, and sales solutions, along with strategic consulting and organizational capability development into one company - and with one name—Amplity. Amplity is a new pure-play pharmaceutical commercialization partner that enjoys a 35-year track record. Our client-first passion elevates, accelerates, and amplifies commercial success from product to patient.

CNS Healthcare

Providing mental health and substance use disorder services for children, youth, and adults. No insurance needed. #EndStigma

Intellect Neurosciences

Intellect Neurosciences Inc. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.